Here, we addressed the issue by proposing a combinatorial approach targeting two different tumor-associated antigens (EpCAM and EGFR) with a bivalent bispecific antibody and multivalent costimulatory antibody-fusion proteins with affinities in the lower nanomolar range, respectively. This evidence concerns the gene EGFR and neoplasm.